News | April 17, 2007

FDA Seizes Shelhigh Implantables, Cautions Doctors to Monitor Patients for Infection

April 18, 2007 — Associated Press reports that on Tuesday U.S. marshals and FDA investigators began seizing heart valves and other implantable medical devices made from cow and pig tissue by a New Jersey company because of concerns about their sterility.

The FDA said it had found significant problems in the manufacturing processes at Shelhigh Inc., Union, NJ. It was estimated that one million animal parts and finished products were taken from Shelhigh Inc., Union, NJ, according to spokeswoman Heidi Rebello.

The seized products include pediatric heart valves and conduits, as well as surgical patches, arterial grafts and annuloplasty rings used to help repair heart valves.

The seizure followed an inspection of the company by the FDA last fall. The agency also warned Shelhigh about the problems during meetings and in two warning letters, sent in 2000 and 2005. The earlier letter cited multiple reports of infections and other problems with some of Shelhigh's products.

The tissue-based devices are used in many surgeries, including open-heart surgery in adults, children and infants, and to repair soft tissue during neurosurgery and abdominal, pelvic and thoracic surgery, the FDA said. Critically ill patients, pediatric patients and patients with weakened immune systems may be at greatest risk from the use of these devices, it added.

The FDA recommended doctors consider using alternative devices. Also, doctors should monitor patients with a Shelhigh implant for infections and proper functioning.


Related Content

News | Heart Valve Technology

May 9, 2023 — Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of ...

Home May 09, 2023
Home
News | Heart Valve Technology

February 28, 2023 — On Feb. 27, the U.S. Food and Drug Administration (FDA) issued a Letter to Health Care Providers to ...

Home February 28, 2023
Home
News | Heart Valve Technology

January 23, 2023 — Leakage of the mitral valve due to degenerative prolapse is a common condition known as primary ...

Home January 23, 2023
Home
News | Heart Valve Technology

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has given the approval to market to The Edwards ...

Home January 02, 2023
Home
News | Heart Valve Technology

December 29, 2022 — The Smidt Heart Institute at Cedars-Sinai was named a Mitral Valve Repair Reference Center, a ...

Home December 29, 2022
Home
News | Heart Valve Technology

December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping ...

Home December 14, 2022
Home
News | Heart Valve Technology

November 22, 2022 — CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve ...

Home November 22, 2022
Home
News | Heart Valve Technology

October 18, 2022 — Foldax, Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive ...

Home October 18, 2022
Home
News | Heart Valve Technology

October 18, 2022 — The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its ...

Home October 18, 2022
Home
News | Heart Valve Technology

September 26, 2022 — Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates ...

Home September 26, 2022
Home
Subscribe Now